Cannabidiol and Multiple Sclerosis; Research articles of interest

Multiple sclerosis (MS) is a chronic autoimmune disease in which inflammatory lesions cause damage to the myelin sheath coating the nerve fibers in the central nervous system (CNS) leading to symptoms ranging from numbness in a limb to paralysis ().

The following peer-reviewed articles are available by clicking on the active links.

Cannabinoid Delivery Systems for Pain and Inflammation Treatment. 2018. Bruni, et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222489/
This article contains a detailed explanation of our ‘endocannabinoid system. This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment.  “There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions.”

Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells. 2018. Elliott, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085417/
The researchers in this project chose to use a dose of 20 mg/kg body weight of CBD, which translates to 1.6 mg/kg when converted to human equivalent dose. “Because CBD is non-psychoactive, our studies suggest that CBD may constitute an excellent candidate for the treatment of MS and other autoimmune diseases.”

Review of the neurological benefits of phytocannabinoids. 2018. Maroon and Bost. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938896/
“The use of cannabis-based medicine for the treatment of MS has a long history and its interaction with the ECS shares many of the same pathways of other neurodegenerative conditions.[] “ “Several preclinical studies have used CBD, for both spasticity and neurogenic pain, to augment existing pharmacological treatments.”

Safety and side effects of cannabidiol, a Cannabis sativa constituent. 2011. Bergamashi et al. https://www.ncbi.nlm.nih.gov/pubmed/22129319
“Cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, has multiple pharmacological actions, including anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties.” “chronic use and high doses up to 1,500 mg/day of CBD are reportedly well tolerated in humans.”

The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. 2007. Centonze et al. https://www.ncbi.nlm.nih.gov/pubmed/17626034
“The ability of cannabinoids to modulate both inflammatory and degenerative neuronal damage prompted investigations on the potential benefits of such compounds in multiple sclerosis (MS) and in animal models of this disorder. “ “Our study suggests that targeting the endocannabinoid system might be useful for the treatment of MS.”

Cannabidiol to Improve Mobility in People with Multiple Sclerosis. 2018. Rudroff and Sosnoff. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874292/
“There is evidence that CBD has a number of beneficial pharmacological effects (, ). It is anti-inflammatory, antioxidative, antiemetic, antipsychotic, and neuroprotective.” “…it is our opinion that CBD supplementation maybe advisable for PwMS to reduce fatigue, pain, spasticity, and ultimately improve mobility.”

Neurological aspects of medical use of cannabidiol. CNS Neurol Disord Drug Targets. 2017. Mannucci et al. https://www.ncbi.nlm.nih.gov/pubmed/28412918

“CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases.” “Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies.”